ClinConnect ClinConnect Logo
Search / Trial NCT03801512

Comparing the Efficacy of Steroid, Acupuncture and Platelet Rich Plasma Injection in Patients with Sciatica

Launched by TAIPEI MEDICAL UNIVERSITY HOSPITAL · Jan 10, 2019

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying different treatments for sciatica, a condition that causes pain along the sciatic nerve, often due to issues like herniated discs or spinal stenosis. The trial will compare three types of treatments: steroid injections, acupuncture, and platelet-rich plasma injections. The aim is to find out which treatment is the most effective and safe for relieving sciatica symptoms.

To participate, individuals must be between 20 and 80 years old and have specific types of sciatica that can be confirmed through medical imaging, like X-rays or MRIs. Participants should be able to follow the trial's guidelines and complete the necessary treatments and assessments. It's important to note that some people will not be eligible, such as those with severe neurological issues or recent surgeries related to their back. If you join the trial, you can expect to receive one of the treatments being studied and help contribute to important research that could improve care for others with sciatica.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Female or male, 20 to 80 years of age.
  • 2. Participants who had dermatome between L3 to S1, or participants whose straight leg raising test was positive, or participants had Meyerding Grade I to II spondylolisthesis or herniated intervertebral disc or spinal stenosis diagnosed by X-rays, Magnetic resonance imaging or computed tomography.
  • 3. Participants whose sciatica symptom doesn't have occur time limit.
  • 4. Participants who agreed to follow the trial protocol.
  • 5. Participants who could complete the study treatment and assessments.
  • 6. Participants who had steroid or pain control injection can participate the study after receiving injection more than 3 days.
  • Exclusion Criteria:
  • 1. Participants with severe progressive neurological symptoms (e.g. cauda equina compression).
  • 2. Participants who had undergone surgery for lumbar disc herniation within 6 months.
  • 3. Participants whose sciatica symptom wasn't caused by lumbar radiculopathy.
  • 4. Participants with cardiovascular, liver, kidney, or hematopoietic system diseases, severe psychiatric or psychological disorder, or cancer.
  • 5. Women who were pregnant.
  • 6. Participants with a pacemaker, metal allergy, or severe fear of needles.

About Taipei Medical University Hospital

Taipei Medical University Hospital is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge medical practices with comprehensive patient care, fostering an environment that promotes scientific discovery and the development of new therapies. With a strong commitment to ethical standards and regulatory compliance, Taipei Medical University Hospital collaborates with multidisciplinary teams to enhance patient outcomes and contribute to the global medical community. Through its extensive research programs, the hospital aims to address critical health challenges and improve the quality of life for diverse populations.

Locations

Taipei City, , Taiwan

Patients applied

0 patients applied

Trial Officials

Ray-Jade Chen, PhD

Study Chair

Taipei Medical University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials